Attitudes and Perceptions of Portuguese Psychiatrists and Psychologists on the Clinical Use of Ketamine
DOI:
https://doi.org/10.20344/amp.22815Keywords:
Attitude of Health Personnel, Depressive Disorder, Treatment-Resistant/drug therapy, Ketamine/therapeutic use, Surveys and QuestionnairesAbstract
Introduction: Ketamine has garnered attention for its rapid efficacy in alleviating depressive symptoms in treatment-resistant depression, offering a novel mechanism as a non-monoaminergic agent. Despite its potential, limited research has explored mental health professionals’ perspectives on its use. This study assesses the attitudes, knowledge, and concerns of Portuguese psychiatrists and psychologists regarding the clinical application of ketamine in treatment-resistant depression.
Methods: A cross-sectional survey study was conducted from June 2022 to January 2024 among Portuguese psychiatrists and psychologists. The anonymous online questionnaire assessed perceptions of ketamine’s therapeutic utility, risks, and knowledge sources. Statistical analyses examined subgroup differences by age, sex, profession, and prior psychedelic use.
Results: Among 156 participants (mean age = 37.2; 68.6% female), 53.8% were psychologists, and 46.2% were psychiatrists or trainees in Psychiatry. Only 35.9% reported substantial knowledge of ketamine’s therapeutic potential, while 59% were open to integrating it clinically. The majority expressed interest in training, though 73% raised concerns about inadequate professional training. Significant differences emerged, with psychiatrists reporting higher knowledge levels and openness to ketamine compared to psychologists, while younger professionals showed greater interest in training and usage.
Conclusion: There was a favorable attitude toward ketamine use among Portuguese psychiatrists and psychologists, yet substantial educational gaps remain. Customized training addressing age, sex, and professional background is essential for safe and effective clinical integration of ketamine in treatment-resistant depression. Further studies should focus on longitudinal outcomes of ketamine treatment under standardized protocols to ensure efficacy and safety in clinical practice.
Downloads
References
Nikolin S, Rodgers A, Schwaab A, Bahji A, Zarate C, Vazquez G, et al. Ketamine for the treatment of major depression: a systematic review and meta-analysis. EClinicalMedicine. 2023;62:102127. DOI: https://doi.org/10.1016/j.eclinm.2023.102127
Krystal JH, Kaye AP, Jefferson S, Girgenti MJ, Wilkinson ST, Sanacora G, et al. Ketamine and the neurobiology of depression: toward nextgeneration rapid-acting antidepressant treatments. Proc Natl Acad Sci USA. 2023;120:e2305772120. DOI: https://doi.org/10.1073/pnas.2305772120
Walsh Z, Mollaahmetoglu OM, Rootman J, Golsof S, Keeler J, Marsh B, et al. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. Corrigendum. BJPsych Open. 2022;8:e29. DOI: https://doi.org/10.1192/bjo.2022.5
Lam RW, Kennedy SH, Adams C, Bahji A, Beaulieu S, Bhat V, et al. Canadian network for mood and anxiety treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. Can J Psychiatry. 2024;69:641-87. DOI: https://doi.org/10.1177/07067437241245384
Drozdz SJ, Goel A, McGarr MW, Katz J, Ritvo P, Mattina GF, et al. Ketamine assisted psychotherapy: a systematic narrative review of the literature. J Pain Res. 2022;15:1691-706. DOI: https://doi.org/10.2147/JPR.S360733
Grabski M, McAndrew A, Lawn W, Marsh B, Raymen L, Stevens T, et al. Adjunctive ketamine with relapse prevention–based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry. 2022;179:152-62. DOI: https://doi.org/10.1176/appi.ajp.2021.21030277
Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020;177:125-33. DOI: https://doi.org/10.1176/appi.ajp.2019.19070684
Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat. 2002;23:273-83. DOI: https://doi.org/10.1016/S0740-5472(02)00275-1
Barnett BS, Siu WO, Pope Jr HG. A survey of american psychiatrists’ attitudes toward classic hallucinogens. J Nerv Ment Dis. 2018;206:476- 80. DOI: https://doi.org/10.1097/NMD.0000000000000828
Barnett BS, Arakelian M, Beebe D, Ontko J, Riegal C, Siu WO, et al. American psychiatrists’ opinions about classic hallucinogens and their potential therapeutic applications: a 7-year follow-up survey. Psychedelic Med. 2024;2:1-9. DOI: https://doi.org/10.1089/psymed.2023.0036
Davis AK, Agin-Liebes G, España M, Pilecki B, Luoma J. Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. J Psychoactive Drugs. 2022;54:309- 18. DOI: https://doi.org/10.1080/02791072.2021.1971343
Levin A, Nagib PB, Deiparine S, Gao T, Mitchell J, Davis AK. Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States. Int J Drug Policy. 2022;108:103816. DOI: https://doi.org/10.1016/j.drugpo.2022.103816
Dixon-Ritchie O, Donley CN, Dixon-Ritchie G. From prohibited to prescribed: the rescheduling of MDMA and psilocybin in Australia. Drug Sci Policy Law. 2023;9:1-3. DOI: https://doi.org/10.1177/20503245231198472
Aicher HD, Duffour C, Liechti ME, Zullino D, Gasser P. Treatment recommendations Psychedelic-assisted therapy (PAT). 2024. [cited 2024 Oct 22]. Available from: https://swisspsychedelic.ch/wp-content/ uploads/2024/09/Treatment_recommendations_PAT.pdf. DOI: https://doi.org/10.4414/sanp.2024.1488043038
Hatfield SP, Thornton NL, Greenstien K, Glozier N. A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia. Aust N Z J Psychiatry. 2024;58:00048674241240597. DOI: https://doi.org/10.1177/00048674241240597
Brandt J. A roadmap for psychedelic pharmacy in Canada: a proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness. Drug Sci Policy Law. 2023;9:20503245231170340. DOI: https://doi.org/10.1177/20503245231170340
Fancy F, Rodrigues NB, Di Vincenzo JD, Chau EH, Sethi R, Husain MI, et al. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression. Bipolar Disord. 2023;21:420-9. DOI: https://doi.org/10.1176/appi.focus.23021022
Hietamies TM, McInnes LA, Klise AJ, Worley MJ, Qian JJ, Williams LM, et al. The effects of ketamine on symptoms of depression and anxiety in real-world care settings: a retrospective controlled analysis. J Affect Disord. 2023;335:484-92. DOI: https://doi.org/10.1016/j.jad.2023.04.141
Hearn BG, Brubaker MD, Richardson G. Counselors’ attitudes toward psychedelics and their use in therapy. J Couns Dev. 2022;100:364-73. DOI: https://doi.org/10.1002/jcad.12429
Wang E, Mathai DS, Gukasyan N, Nayak S, Garcia-Romeu A. Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among US healthcare professionals. Scientific Reports. 2024;14:28022. DOI: https://doi.org/10.1038/s41598-024-78736-1
Shen Z, Gao D, Lv X, Wang H, Yue W. A meta-analysis of the effects of ketamine on suicidal ideation in depression patients. Transl Psychiatry. 2024;14:248. DOI: https://doi.org/10.1038/s41398-024-02973-1
Kucsera A, Suppes T, Haug NA. Psychologists’ and psychotherapists’ knowledge, attitudes, and clinical practices regarding the therapeutic use of psychedelics. Clin Psychol Psychother. 2023;30:1369-79. DOI: https://doi.org/10.1002/cpp.2880
Bright S, Williams M. Should Australian psychology consider enhancing psychotherapeutic interventions with psychedelic drugs? A call for research. Aust Psychol. 2018;53:467-76. DOI: https://doi.org/10.1111/ap.12345
Gorman I, Nielson EM, Molinar A, Cassidy K, Sabbagh J. Psychedelic harm reduction and integration: a transtheoretical model for clinical practice. Front Psychol. 2021;12:645246. DOI: https://doi.org/10.3389/fpsyg.2021.645246
Gründer G, Brand M, Mertens LJ, Jungaberle H, Kärtner L, Scharf DJ, et al. Treatment with psychedelics is psychotherapy: beyond reductionism. Lancet Psychiatry. 2024;11:231-6. DOI: https://doi.org/10.1016/S2215-0366(23)00363-2
Penn AD, Phelps J, Rosa WE, Watson J. Psychedelic-assisted psychotherapy practices and human caring science: toward a careinformed model of treatment. J Humanist Psychol. 2024;64:592-617. DOI: https://doi.org/10.1177/00221678211011013
Phelps J. Developing guidelines and competencies for the training of psychedelic therapists. J Humanist Psychol. 2017;57:450-87. DOI: https://doi.org/10.1177/0022167817711304
Phelps J, Henry J. Foundations for training psychedelic therapists. Curr Top Behav Neurosci. 2022;56:93-109. DOI: https://doi.org/10.1007/7854_2021_266
Pilecki B, Luoma JB, Bathje GJ, Rhea J, Narloch VF. Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduct J. 2021;18:40. DOI: https://doi.org/10.1186/s12954-021-00489-1
Figueiredo IC, Corvacho M, Mota P. Psicadélicos em saúde mental. 1st ed. Lisbon: Edições Lidel; 2023.
Mota P, Castro-Rodrigues P, Cunha C, Figueiredo IC, Bastos J, Rosa MT, Marta P, et al. Uso clínico de cetamina para perturbações psiquiátricas: recomendações de boas práticas e padronização de intervenções. 2023. [cited 2024 Oct 24]. Available from: https://space.com.pt/docs/ space-uso-clinico-de-cetamina-para-perturbacoes-psiquiatricas.pdf.
Seybert C, Cotovio G, Madeira L, Ricou M, Pires AM, Oliveira-Maia AJ. Psychedelic treatments for mental health conditions pose challenges for informed consent. Nat Med. 2023;29:2167-70. DOI: https://doi.org/10.1038/s41591-023-02378-5
Bahji A, Zarate CA, Vazquez GH. Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert Opin Drug Saf. 2022;21:853-66. DOI: https://doi.org/10.1080/14740338.2022.2047928
Kryst J, Kawalec P, Mitoraj AM, Pilc A, Lasoń W, Brzostek T. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep. 2020;72:543-62. DOI: https://doi.org/10.1007/s43440-020-00097-z
Memon RI, Naveed S, Faquih AE, Fida A, Abbas N, Chaudhary AM. Effectiveness and safety of ketamine for unipolar depression: a systematic review. Psychiatr Q. 2020;91:1147-92. DOI: https://doi.org/10.1007/s11126-020-09830-6
Hovda N, Gerrish W, Frizzell W, Shackelford R. A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders. J Affect Disord. 2024;345:262-71. DOI: https://doi.org/10.1016/j.jad.2023.10.120
Van Amsterdam J, Van Den Brink W. Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. Expert Opin Drug Saf. 2022;21:83-94. DOI: https://doi.org/10.1080/14740338.2021.1949454
Le TT, Di Vincenzo JD, Teopiz KM, Lee Y, Cha DS, Lui LM, et al. Ketamine for psychotic depression: an overview of the glutamatergic system and ketamine’s mechanisms associated with antidepressant and psychotomimetic effects. Psychiatry Res. 2021;306:114231. DOI: https://doi.org/10.1016/j.psychres.2021.114231
da Frota Ribeiro CM, Sanacora G, Hoffman R, Ostroff R. The use of ketamine for the treatment of depression in the context of psychotic symptoms: to the editor. Biol Psychiatry. 2016;79:e65-6. DOI: https://doi.org/10.1016/j.biopsych.2015.05.016
Veraart JK, Smith-Apeldoorn SY, Spijker J, Kamphuis J, Schoevers RA. Ketamine treatment for depression in patients with a history of psychosis or current psychotic symptoms: a systematic review. J Clin Psychiatry. 2021;82:20r13459. DOI: https://doi.org/10.4088/JCP.20r13459
Morgan CJ, Rees H, Curran HV. Attentional bias to incentive stimuli in frequent ketamine users. Psychol Med. 2008;38:1331-40. DOI: https://doi.org/10.1017/S0033291707002450
Kolp E, Friedman HL, Young MS, Krupitsky E. Ketamine enhanced psychotherapy: preliminary clinical observations on its effectiveness in treating alcoholism. Humanist Psychol. 2006;34:399-422. DOI: https://doi.org/10.1207/s15473333thp3404_7
Wong A, Benedict NJ, Armahizer MJ, Kane-Gill SL. Evaluation of adjunctive ketamine to benzodiazepines for management of alcohol withdrawal syndrome. Ann Pharmacother. 2015;49:14-9. DOI: https://doi.org/10.1177/1060028014555859
Jones JL, Mateus CF, Back SE. Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psychiatry. 2018;9:372390. DOI: https://doi.org/10.3389/fpsyt.2018.00277
Famuła A, Radoszewski J, Czerwiec T, Sobiś J, Więckiewicz G. Ketamine in substance use disorder treatment: a narrative review. Alpha Psychiatry. 2024;25:206. DOI: https://doi.org/10.5152/alphapsychiatry.2024.241522
Grover C, Monds L, Montebello M. A survey of Australian psychiatrists’ and psychiatry trainees’ knowledge of and attitudes towards psychedelics in the treatment of psychiatric disorders. Australas Psychiatry. 2023;31:329-35. DOI: https://doi.org/10.1177/10398562231155125
Kraiem E, Diener M, Guss J, Mavrides L, Saban S. Psychoanalyst attitudes towards psychedelic-assisted therapy. Drugs Educ Prev Polic. 2024:1-12. DOI: https://doi.org/10.1080/09687637.2024.2359444
Emmerich N, Humphries B. Is the requirement for first-person experience of psychedelic drugs a justified component of a psychedelic therapist’s training? Camb Q Healthc Ethics. 2023:1-10. DOI: https://doi.org/10.1017/S0963180123000099
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
